RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-13 Earnings release - Q1 2027

More about the company

Quotes

Date	Price	Change	Volume
27/07/26	¥74.00	0.00%	770,300
24/07/26	¥74.00	-3.90%	1,661,500
23/07/26	¥77.00	+2.67%	651,400
22/07/26	¥75.00	0.00%	1,518,500
21/07/26	¥75.00	+2.74%	2,074,500

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 09:30:00 27/07/2026 +03			5-day change	1st Jan Change
74.00 ^JPY	0.00%		-1.33%	-5.13%

07-02	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
07-02	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI

Market Cap	4.18B 25.56M 22.45M 20.88M 19.16M 36M 2.46B 36.56M 248M 96.87M 1.21B 95.96M 93.9M	P/E 2025	-3.89x	P/E 2026	-3.82x
Enterprise Value	1.36B 8.29M 7.28M 6.77M 6.22M 11.68M 799M 11.86M 80.44M 31.43M 393M 31.13M 30.46M	EV / Sales 2025	666x	EV / Sales 2026	651x
Free-Float	96.35%	Yield 2025 *	-	Yield 2026	-

07-02	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment	MT
07-02	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia	CI
05-14	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
03-19	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan	MT
03-19	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment	CI
03-10	Ribomic Reports Positive Phase II Results For Achondroplasia Drug	MT
03-10	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia	CI
02-12	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-14	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006	MT
01-14	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy	CI
11-21	Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial	MT
07/10/25	Ribomic Reports Positive Phase 2 Results for Achondroplasia Drug Umedaptanib Pegol	MT
07/10/25	Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and Older	CI

07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older	BU
05/11/24	RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort	BU
03/08/24	RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study	BU
05/12/23	RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	BU
29/07/22	RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	PU

Ribomic Inc. Stock

Stocks

4591

JP3974850004

Biotechnology & Medical Research

Valuation: Ribomic Inc.

Chart: Ribomic Inc.

Latest news : Ribomic Inc.

Press Releases: Ribomic Inc.

News in other languages: Ribomic Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ribomic Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

08/10/25	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
06/11/24	RIBOMIC gibt positive Zwischenergebnisse der Phase-IIa-Studie mit Umedaptanib Pegol bei Achondroplasie bekannt, die eine Steigerung der annualisierten Wachstumsrate von bis zu +4,6 cm/Jahr bei Kindern ab 5 Jahren in der niedrig dosierten...
20/02/20	RIBOMIC : kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
19/06/19	RIBOMIC : gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt

1 week	-1.33%
Current month	+21.31%
1 month	+21.31%
3 months	-7.50%
6 months	-14.94%
Current year	-5.13%

Manager	Title	Age	Since
Yoshikazu Nakamura PSD	President	78	01/04/2012
Toshiya Imai DFI	Director of Finance/CFO	-	-
Takeo Adachi CTO	Chief Tech/Sci/R&D Officer	38	01/10/2023

Director	Title	Age	Since
Toshiaki Nishihata BRD	Director/Board Member	77	01/06/2016
Yoshikazu Nakamura BRD	Director/Board Member	78	01/10/2005
Makoto Kaiami BRD	Director/Board Member	74	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RIBOMIC INC.	0.00%	-1.33%	-24.49%	-50.99%	25.56M
ARGENX SE	-0.35%	+6.40%	+56.66%	+70.92%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+80.66%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+425.15%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.53%	-15.34%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-1.13%	+1.05%	+20.81%	-7.73%	20.46B
GENMAB A/S	+0.43%	+1.87%	+25.64%	-30.06%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.10%	+1.88%	+34.42%	+545.91%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+310.94%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+179.36%	13.92B
Average	-0.83%	+1.29%	+32.62%	+150.88%	24.01B
Weighted average by Cap.	-1.02%	+2.10%	+38.40%	+136.86%

	2025	2026
Net sales	2M 12.22K 10.73K 9.98K 9.16K 17.21K 1.18M 17.47K 119K 46.3K 578K 45.87K 44.88K	3M 18.33K 16.1K 14.97K 13.74K 25.81K 1.76M 26.21K 178K 69.45K 868K 68.8K 67.32K
Net income	-1.02B -6.22M -5.46M -5.08M -4.66M -8.76M -599M -8.89M -60.32M -23.57M -294M -23.35M -22.84M	-1.14B -6.99M -6.14M -5.71M -5.24M -9.85M -674M -10M -67.84M -26.51M -331M -26.26M -25.69M
Net Debt	-3.04B -18.55M -16.29M -15.15M -13.91M -26.13M -1.79B -26.53M -180M -70.3M -878M -69.65M -68.15M	-2.83B -17.27M -15.17M -14.11M -12.94M -24.32M -1.66B -24.7M -168M -65.44M -818M -64.83M -63.43M

1 week	70	78
1 month	58	113
Current year	57	120
1 year	57	127
3 years	57	155
5 years	57	944
10 years	57	1,109